Abstract
Glioblastoma multiforme is a very aggressive central nervous system tumor with a high celular replacement, local infiltration, degradation of the extracellular matrix and resistance to surgery and chemotherapeutical agents. General survival used to be less than 2 years. However, research in the last years has shown the molecular mechanisms underlying behavior and potentially be a therapeutical targets. We show an adult with 20 years old diagnosed with glioblastoma multiforme when he was 13 years, whose treatment involved resective surgery, chemoterapy and ketogenic diet. Genetic characterization was performed and analyzed in the context of the clinical pathway.
References
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. 4.a ed. Revisada. Lyon: International Agency for Research on Cancer; 2016. doi: 10.2176/nmc.ra.2017-0010.
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.
Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434-52. doi: 10.1038/nrclinonc.2016.204.
Amelot A, De Cremoux P, QuiHien V, Polivka M, Adle-Biassette H, Lehmann-Che J, et al. IDH-mutation is a weak predictor of long-termsurvival in glioblastoma patients. Plos One. 2015;10(7):e0130596. doi: 10.1371/journal.pone.0130596.
Crespo I, Vital AL, Gonzalez-Tablas M, Patino MC, Otero A, Lopes MC, et al. Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol. 2015;185(7):1820-33. doi: 10.1016/j.ajpath.2015.02.023.
Li QJ, Cai JQ, Liu CY. Evolving molecular genetics of glioblastoma: Chin Med J (Engl). 2016;129(4):464-71. doi: 10.4103/0366-6999.176065.
Trujillo FG, Noriega CC, Castro OJ, Olaya N, Penagos PJ, Zubieta C. Glioblastoma multiforme: actualidad en marcadores biomoleculares como factores de pronóstico a propósito de una serie de casos con sobrevida mayor a 2 años en el Instituto Nacional de Cancerologia. INC- Colombia. Acta Neurol Colomb. 2014;30(4):282-9.
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550-63. doi: 10.1016/j.cell.2015.12.028.
Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glio-blastoma multiforme, diagnosis and treatment; recent literature review. Curr Med Chem. 2017;24(27). doi: 10.2174/0929867324666170516123206.
Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neuroon-col. 2014;117(1):125-31. doi: 10.1007/s11060-014-1362-0.
Maroon J, Bost J, Amos A, Zuccoli G. Restricted calorie keto-genic diet for the treatment of glioblastoma multiforme. J Child Neurol. 2013;28(8):1002-8. doi: 10.1177/0883073813488670.
Winter SF, Loebel F, Dietrich J. Role of ketogenic metabolic therapy in malignant glioma: A systematic review. Crit Rev Oncol Hematol. 2017;112:41-58. doi: 10.1016/j.critrev-onc.2017.02.016.
Sun Y, Goderie SK, Temple S. Asymmetric distribution of EGFR receptor during mitosis generates diverse CNS progenitor cells. Neuron. 2005;45(6):873-86. doi: 10.1016/j.neuron.2005.01.045.
Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wòhrer A, Marosi C, Hegi M, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro Oncol. 2017;19:1460-8. doi: 10.1093/neuonc/nox054.
Luoto S, Hermelo I, Vuorinen EM, Hannus P, Kesseli J, Nykter M, Granberg KJ. Computational characterization of suppressive immune microenvironments in glioblastoma. Cancer Res. 2018;78:5574-85. doi: 10.1158/0008-5472.CAN-17-3714.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. doi: 10.1056/NEJMoa043331.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-7. doi: 10.1126/science.275.5308.1943.
Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246-56. doi: 10.1093/jnci/93.16.1246.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.